CRISPR Base and Prime Editing in Ageing Research

What Base and Prime Editing Do

Conventional CRISPR nucleases commonly begin by cutting both strands of DNA and relying on cellular repair. Base and prime editing instead couple programmable DNA recognition to enzymes that write a defined sequence change. They still engage cellular repair pathways, and they can still produce unwanted outcomes, but a deliberate double-strand break is not the central editing step. [1] [3] [8]

Cytosine base editors were first developed to produce C•G-to-T•A substitutions, while adenine base editors produce A•T-to-G•C substitutions. A guide RNA positions the editor over a short activity window, so other compatible bases within that window may also be changed. [1] [2] [7]

A prime editor combines a Cas9 nickase with a reverse transcriptase. Its prime-editing guide RNA identifies the genomic site and carries a template encoding the intended change. This design supports all twelve possible base substitutions as well as selected small insertions and deletions, but editing efficiency varies substantially with the locus, cell type, guide design, and editor configuration. [3] [9]

Why These Tools Matter to Ageing Research

These editors have two distinct roles in the field. As research tools, they can create isogenic cell or animal models that differ at a selected variant, helping investigators test whether that variant alters an age-related phenotype. As potential therapeutics, they could correct a causal mutation or install a protective sequence change in a relevant tissue. Prime-edited patient-derived organoids have already shown that precise editing can generate and repair disease models, although this work was not a study of organismal ageing. [10]

The distinction between a defined genetic disease and ageing itself is important. A single pathogenic allele can be a clear editing target; normal ageing reflects many interacting molecular, cellular, and systemic changes rather than one shared sequence error. Successful correction of one mutation therefore does not imply that the same strategy can reverse ageing across tissues. [4] [11]

Editing Strategies and Their Limits

Progeria: The Clearest Ageing-Related Example

Hutchinson–Gilford progeria syndrome is usually caused by a single C-to-T substitution in LMNA. Although the substitution does not change the encoded amino acid, it activates abnormal RNA splicing and produces progerin, a toxic lamin A variant associated with severe vascular disease and shortened lifespan. The syndrome shares selected features with ageing but has a distinct monogenic cause and clinical course. [4] [5]

In patient-derived fibroblasts, an adenine base editor corrected the pathogenic allele, improved normal LMNA splicing, reduced progerin, and improved nuclear morphology. In a mouse model carrying the human mutation, systemic dual-AAV9 delivery produced durable editing in several tissues, reduced vascular pathology, and increased median lifespan from 215 to 510 days. This survival result was obtained in a homozygous transgenic disease model after treatment early in life, which limits direct extrapolation to the genetically diverse biology of human ageing. [4]

This study provides unusually strong proof of mechanism because the disease has a defined causal variant and measurable downstream product. It does not show that base editing slows normal ageing, nor that correcting LMNA would benefit people without the pathogenic progeria allele. [4] [5]

Prime Editing of Age-Related Disease Variants

An optimized dual-AAV prime-editing system has been tested in mouse brain, liver, and heart. Investigators used it to install the rare APOE3 Christchurch R136S variant in mouse astrocytes and a Pcsk9 variant associated with lower LDL cholesterol in hepatocytes. Editing reached relevant cell populations, and the study did not detect off-target editing at the sites examined or evident liver toxicity under its experimental conditions. [6]

The experiment demonstrated in-vivo sequence installation, not protection from Alzheimer’s disease, cardiovascular events, or age-related functional decline. The APOE variant was treated as a candidate protective allele, and the mice were assessed over a limited period rather than through an ageing or lifespan study. It therefore supports prime editing as a platform for mechanistic research more directly than it supports a longevity intervention. [6]

Delivery and Safety

Delivery is a major bottleneck because the editor, guide, and regulatory elements must reach the right cells at sufficient levels. The progeria study split the base editor between two AAV vectors, and the in-vivo prime-editing study also used multi-vector systems because a full prime editor exceeds the normal packaging capacity of one AAV. Editing efficiencies differed across organs, showing that a successful construct is not automatically a whole-body delivery system. [4] [6]

Sequence safety has several layers. A guide can direct editing to partially matched genomic sites; a base editor can alter additional compatible bases within its activity window; deaminase components can have guide-independent activity; and prime-editing configurations can produce indels or other unintended products at the intended site. More selective base editors and modified prime-editor nickases can reduce particular error classes, but performance must be measured for the specific editor, guide, cell type, dose, and delivery method. [7] [8] [9]

Biological safety extends beyond sequence measurements. Persistent editor expression, immune responses to bacterial Cas proteins or viral vectors, uneven editing among cell types, and the consequences of altering a risk-associated allele all require long-term evaluation. The absence of a detected signal in a small preclinical study is bounded by the tissues, time points, and assays that were examined. [4] [6] [9]

Evidence Quality and Interpretation

Confidence is high that base and prime editors can make defined sequence changes in cultured mammalian cells, and there is replicated preclinical evidence of editing in multiple mouse tissues. The progeria study also connects correction of a causal allele to molecular, pathological, and survival outcomes in a disease model. [1] [2] [3] [4] [6]

Confidence is low that these methods can modify normal human ageing. Most relevant evidence concerns platform development, cultured models, young or adult mice, or diseases with discrete genetic causes. None of the cited studies demonstrates slowed multisystem ageing or extended healthspan in humans. Claims about general rejuvenation therefore go beyond the available evidence. [4] [6] [10]

Summary

CRISPR base and prime editing allow researchers to test and alter selected DNA variants with more controlled sequence outcomes than double-strand-break-based editing can provide in many contexts. Their clearest ageing-related application is the preclinical correction of a causal progeria mutation; other work has installed candidate protective variants or built precise disease models. These results make the technologies valuable experimental tools, but they do not establish a treatment for normal ageing. Translational progress depends on causal target selection, tissue-specific delivery, comprehensive error measurement, and long-term biological safety. [4] [6] [9]

References

1. Komor, A. C. et al. "Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage." Nature (2016). https://doi.org/10.1038/nature17946
2. Gaudelli, N. M. et al. "Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage." Nature (2017). https://doi.org/10.1038/nature24644
3. Anzalone, A. V. et al. "Search-and-replace genome editing without double-strand breaks or donor DNA." Nature (2019). https://doi.org/10.1038/s41586-019-1711-4
4. Koblan, L. W. et al. "In vivo base editing rescues Hutchinson–Gilford progeria syndrome in mice." Nature (2021). https://doi.org/10.1038/s41586-020-03086-7
5. Merideth, M. A. et al. "Phenotype and course of Hutchinson–Gilford progeria syndrome." New England Journal of Medicine (2008). https://doi.org/10.1056/NEJMoa0706898
6. Davis, J. R. et al. "Efficient prime editing in mouse brain, liver and heart with dual AAVs." Nature Biotechnology (2024). https://doi.org/10.1038/s41587-023-01758-z
7. Gehrke, J. M. et al. "An APOBEC3A-Cas9 base editor with minimized bystander and off-target activities." Nature Biotechnology (2018). https://doi.org/10.1038/nbt.4199
8. Lee, J. et al. "Prime editing with genuine Cas9 nickases minimizes unwanted indels." Nature Communications (2023). https://doi.org/10.1038/s41467-023-37507-8
9. Anzalone, A. V., Koblan, L. W. & Liu, D. R. "Genome editing with CRISPR–Cas nucleases, base editors, transposases and prime editors." Nature Biotechnology (2020). https://doi.org/10.1038/s41587-020-0561-9
10. Schene, I. F. et al. "Prime editing for functional repair in patient-derived disease models." Nature Communications (2020). https://doi.org/10.1038/s41467-020-19136-7
11. López-Otín, C. et al. "Hallmarks of Aging: An Expanding Universe." Cell (2023). https://doi.org/10.1016/j.cell.2022.11.001